![](/img/cover-not-exists.png)
A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer
D.Scott McMeekin, Alan Gordon, Jeffrey Fowler, Allen Melemed, Richard Buller, Thomas Burke, Jeffery Bloss, Paul SabbatiniVolume:
90
Year:
2003
Language:
english
Pages:
6
DOI:
10.1016/s0090-8258(03)00203-8
File:
PDF, 71 KB
english, 2003